Literature DB >> 10757936

Equal Biliopancreatic and Alimentary Limbs: An Analysis of 106 Cases over 5 Years.

.   

Abstract

In 106 consecutive biliopancreatic diversion patients, the small intestine was divided at its mid-point to create equal biliopancreatic and alimentary limbs, because several observations had suggested that this would lead to Improved nutrition post-operatively. In order to test this hypothesis, the progress of these patients was compared with a similar group who had undergone a standard Scopinaro biliopancreatic diversion with a 250 cm alimentary limb. Four particular areas were studied: weight loss, hypoproteinemia, iron deficiency anemia and disturbance of bone metabolism. Patients with equal limbs lost 71 % of their excess weight at 36 months, compared to 77% in the standard diversion. With the equal limbs the incidence of hypoproteinemia was reduced from 8% to 2% and the incidence of iron deficiency anemia decreased from 20% to 10%. The change had no effect on clinically symptomatic metabolic bone disturbance which occurred in 7% of the patients in both groups. In the authors opinion, these improvements justify continued division of the small intestine at its mid-point.

Entities:  

Year:  1993        PMID: 10757936     DOI: 10.1381/096089293765559340

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  3 in total

1.  Intestinal obstruction following biliopancreatic diversion.

Authors:  Mark F Blake; Amit J Dwivedi; Bruce Macpherson
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

Review 2.  Evidence-based medicine: open and laparoscopic bariatric surgery.

Authors:  P Gentileschi; S Kini; M Catarci; M Gagner
Journal:  Surg Endosc       Date:  2002-01-04       Impact factor: 4.584

3.  Conversion of proximal to distal gastric bypass for failed gastric bypass for superobesity.

Authors:  H J Sugerman; J M Kellum; E J DeMaria
Journal:  J Gastrointest Surg       Date:  1997 Nov-Dec       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.